Evidence map›Paper›PMID 39596692›Full record

ReviewGenes2024

Application of CRISPR/Cas9 Technology in Rice Germplasm Innovation and Genetic Improvement.

Jijin Chen, Zhening Miao, Deyan Kong, Anning Zhang, Feiming Wang, Guolan Liu, Xinqiao Yu, Lijun Luo, Yi Liu

Abstract readReview
In one paragraph

Review in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jijin ChenShanghai Agrobiological Gene Center, Shanghai 201106, China.
Zhening MiaoShanghai Agrobiological Gene Center, Shanghai 201106, China.
Deyan KongShanghai Agrobiological Gene Center, Shanghai 201106, China.
Anning ZhangShanghai Agrobiological Gene Center, Shanghai 201106, China.ORCID 0000-0001-5971-5527
Feiming WangShanghai Agrobiological Gene Center, Shanghai 201106, China.
Guolan LiuShanghai Agrobiological Gene Center, Shanghai 201106, China.
Xinqiao YuShanghai Agrobiological Gene Center, Shanghai 201106, China.
Lijun LuoShanghai Agrobiological Gene Center, Shanghai 201106, China.
Yi LiuShanghai Agrobiological Gene Center, Shanghai 201106, China.ORCID 0000-0002-3965-6299

Funding

Shanghai Municipal Commission of Science and technology 23N11900100The Bill and Melinda Gates Foundation INV-033236-3
6 · The paper itself

Abstract

Improving the efficiency of germplasm innovation has always been the aim of rice breeders. Traditional hybrid breeding methods for variety selection rarely meet the practical needs of rice production. The emergence of genome-editing technologies, such as CRISPR/Cas9, provides a new approach to the genetic improvement of crops such as rice. The number of published scientific papers related to "gene editing" and "CRISPR/Cas9" retrievable on websites both from China and other countries exhibited an increasing trend, year by year, from 2014 to 2023. Research related to gene editing in rice accounts for 33.4% and 12.3% of all the literature on gene editing published in China and other countries, respectively, much higher than that on maize and wheat. This article reviews recent research on CRISPR/Cas9 gene-editing technology in rice, especially germplasm innovation and genetic improvement of commercially promoted varieties with improved traits such as disease, insect, and herbicide resistance, salt tolerance, quality, nutrition, and safety. The aim is to provide a reference for the precise and efficient development of new rice cultivars that meet market demand.

Indexed as

CRISPR-Cas SystemsGene EditingOryzaPlant BreedingCrops, AgriculturalGenome, PlantPlants, Genetically ModifiedCRISPR/Cas9gene editinggenetic improvementrice

Identifiers

PMID39596692
PMCPMC11593773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.